Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Grutters

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Vaccine|August 14, 2017
Pneumococcal conjugate vaccination response in patients after community-acquired pneumonia, differences in patients with S. pneumoniae versus other pathogensG H J Wagenvoort, B J M Vlaminckx, D A van Kessel, et al.
Clinical and Experimental Immunology|February 1, 2012
Bronchoalveolar lavage cell pattern from healthy human lungM Heron, J C Grutters, K M ten Dam-Molenkamp, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|September 6, 2013
YKL-40 and matrix metalloproteinases as potential biomarkers of inflammation and fibrosis in the development of bronchiolitis obliterans syndromeE A Kastelijn, C H M van Moorsel, H J T Ruven, et al.
Tissue Antigens|January 11, 2011
Genetic variation in GREM1 is a risk factor for fibrosis in pulmonary sarcoidosisM Heron, C H M van Moorsel, J C Grutters, et al.
Genes and Immunity|July 24, 2009
Variation in IL7R predisposes to sarcoid inflammationM Heron, J C Grutters, C H M van Moorsel, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|March 7, 2013
Endpoints for clinical trials of sarcoidosisR P Baughman, M Drent, D A Culver, et al.
Clinical and Experimental Immunology|June 15, 2007
Linkage between Toll-like receptor (TLR) 2 promotor and intron polymorphisms: functional effects and relevance to sarcoidosisM Veltkamp, P A H M Wijnen, C H M van Moorsel, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|July 30, 2011
Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task ForceR P Baughman, S Nagai, M Balter, et al.
Tissue Antigens|November 15, 2007
Complement receptor 1 single nucleotide polymorphisms in Czech and Dutch patients with sarcoidosisF Mrazek, M Kvezereli, E Garr, et al.
Tissue Antigens|July 31, 2007
Analysis of BTNL2 genetic polymorphisms in British and Dutch patients with sarcoidosisP Spagnolo, H Sato, J C Grutters, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Vaccine|August 14, 2017
Pneumococcal conjugate vaccination response in patients after community-acquired pneumonia, differences in patients with S. pneumoniae versus other pathogensG H J Wagenvoort, B J M Vlaminckx, D A van Kessel, et al.
Clinical and Experimental Immunology|February 1, 2012
Bronchoalveolar lavage cell pattern from healthy human lungM Heron, J C Grutters, K M ten Dam-Molenkamp, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|September 6, 2013
YKL-40 and matrix metalloproteinases as potential biomarkers of inflammation and fibrosis in the development of bronchiolitis obliterans syndromeE A Kastelijn, C H M van Moorsel, H J T Ruven, et al.
Tissue Antigens|January 11, 2011
Genetic variation in GREM1 is a risk factor for fibrosis in pulmonary sarcoidosisM Heron, C H M van Moorsel, J C Grutters, et al.
Genes and Immunity|July 24, 2009
Variation in IL7R predisposes to sarcoid inflammationM Heron, J C Grutters, C H M van Moorsel, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|March 7, 2013
Endpoints for clinical trials of sarcoidosisR P Baughman, M Drent, D A Culver, et al.
Clinical and Experimental Immunology|June 15, 2007
Linkage between Toll-like receptor (TLR) 2 promotor and intron polymorphisms: functional effects and relevance to sarcoidosisM Veltkamp, P A H M Wijnen, C H M van Moorsel, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|July 30, 2011
Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task ForceR P Baughman, S Nagai, M Balter, et al.
Tissue Antigens|November 15, 2007
Complement receptor 1 single nucleotide polymorphisms in Czech and Dutch patients with sarcoidosisF Mrazek, M Kvezereli, E Garr, et al.
Tissue Antigens|July 31, 2007
Analysis of BTNL2 genetic polymorphisms in British and Dutch patients with sarcoidosisP Spagnolo, H Sato, J C Grutters, et al.
Pageof 8